Literature DB >> 21557643

Immune response in patients receiving a bioprosthetic heart valve: lack of response with decellularized valves.

Oliver Bloch1, Pia Golde, Pascal M Dohmen, Steffen Posner, Wolfgang Konertz, Wilhelm Erdbrügger.   

Abstract

Conventional biological heart valves treated with glutaraldehyde (GA) reveal a limited lifespan due to calcification. This is assumed to be an immune response initiated process, which is not seen with decellularized valves. However, their immunological potential is still a matter of debate. Therefore, serum samples from patients undergoing heart valve surgery were obtained before (Pre), after (Post), and 9-12 months after operation (Follow Up). Immunoglobulin G (IgG) and M (IgM) antibodies against porcine collagen I and α-Gal (Gal-alpha1,3-Gal-beta1,4-GlcNac-R) were determined for decellularized and GA treated valves. Antibody titers for collagen type I revealed no significant alteration for both types of valves. However, a considerable anti-α-Gal antibody response was observed in patients with GA-treated porcine valves. In detail, IgM antibodies were increased during follow up (p<0.05), whereas decellularized valves revealed a minor decrease in the IgM response (p<0.001). IgG antibodies were considerably increased with GA-treated porcine (p<0.05) and bovine (p<0.01) xenografts, whereas there was lack of response with decellularized valves. This indicates that GA treatment is not sufficient to eliminate immune response to the α-Gal epitope completely. Future investigations will have to verify whether immune response to α-Gal can be linked to the limited durability of conventional valves. © Mary Ann Liebert, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557643     DOI: 10.1089/ten.TEA.2011.0046

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  20 in total

Review 1.  How to make a heart valve: from embryonic development to bioengineering of living valve substitutes.

Authors:  Donal MacGrogan; Guillermo Luxán; Anita Driessen-Mol; Carlijn Bouten; Frank Baaijens; José Luis de la Pompa
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Immunogenicity in xenogeneic scaffold generation: antigen removal vs. decellularization.

Authors:  Maelene L Wong; Leigh G Griffiths
Journal:  Acta Biomater       Date:  2014-01-31       Impact factor: 8.947

Review 3.  Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions.

Authors:  Daniel Y Cheung; Bin Duan; Jonathan T Butcher
Journal:  Expert Opin Biol Ther       Date:  2015-06-01       Impact factor: 4.388

4.  Magnesium Presence Prevents Removal of Antigenic Nuclear-Associated Proteins from Bovine Pericardium for Heart Valve Engineering.

Authors:  Ailsa J Dalgliesh; Zhi Zhao Liu; Leigh G Griffiths
Journal:  Tissue Eng Part A       Date:  2017-03-10       Impact factor: 3.845

5.  Absence of immune responses with xenogeneic collagen and elastin.

Authors:  Alexandra Bayrak; Pauline Prüger; Ulrich A Stock; Martina Seifert
Journal:  Tissue Eng Part A       Date:  2013-04-15       Impact factor: 3.845

6.  Porcine or bovine valve replacement in 3 patients with IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose.

Authors:  Susan M Mozzicato; Anubha Tripathi; Jonathon B Posthumus; Thomas A E Platts-Mills; Scott P Commins
Journal:  J Allergy Clin Immunol Pract       Date:  2014-07-25

7.  Successful implantation of a decellularized equine pericardial patch into the systemic circulation.

Authors:  Pascal Maria Dohmen; Francisco da Costa; Sergio Vega Lopes; Ricardo Vilani; Oliver Bloch; Wolfgang Konertz
Journal:  Med Sci Monit Basic Res       Date:  2014-01-10

8.  Extracellular matrix in deoxycholic acid decellularized aortic heart valves.

Authors:  Oliver Bloch; Wilhelm Erdbrügger; Wolfgang Völker; Alexander Schenk; Steffen Posner; Wolfgang Konertz; Pascal M Dohmen
Journal:  Med Sci Monit       Date:  2012-12

9.  Mechanical compliance and immunological compatibility of fixative-free decellularized/cryopreserved human pericardium.

Authors:  Maria Cristina Vinci; Giulio Tessitore; Laura Castiglioni; Francesca Prandi; Monica Soncini; Rosaria Santoro; Filippo Consolo; Francesca Colazzo; Barbara Micheli; Luigi Sironi; Gianluca Polvani; Maurizio Pesce
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Valved conduit with glutaraldehyde-fixed bovine pericardium treated by anticalcification protocol.

Authors:  Hong-Gook Lim; Gi Beom Kim; Saeromi Jeong; Yong Jin Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.